Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatic Arterial Infusion Chemotherapy Combined With Lenvatinib and PD-1 Inhibitors for Advanced Hepatocellular Carcinoma With Macrovascular or Biliary Invasion: A Multicenter, Controlled Real-World Study

NCT07466225 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT07466225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07466225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatic Arterial Infusion Chemotherapy Combined With Lenvatinib and PD-1 Inhibitors for Advanced Hepatocellular Carcinoma With Macrovascular or Biliary Invasion: A Multicenter, Controlled Real-World Study
Lead sponsor
Peking University
Phase
Observational
Overall status
Active, not recruiting
Start date
May 29, 2026
Completion date
June 30, 2027
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)